 Insmed Incorporated Nasdaq:INSM, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that ARIKAYCE amikacin liposome inhalation suspension has been included in the new international treatment guidelines for nontuberculous mycobacterial NTM lung disease, a chronic, debilitating condition that can cause severe, permanent damage to the lungs. The evidence-based guidelines, issued by the American Thoracic Society ATS, European Respiratory Society ERS, European Society of Clinical Microbiology and Infectious Diseases ESCMID, and Infectious Diseases Society of America IDSA, recommend the use of ARIKAYCE for the treatment of patients with refractory NTM lung disease caused by Mycobacterium avium complex MAC as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. 